98%
921
2 minutes
20
Background: Shared decision-making (SDM) is a patient-centred approach to improve the quality of care. An essential requirement for the SDM process is to be fully aware of patient information needs.
Objectives: Our study aimed to assess patient information needs for new antidiabetic medications using the best-worst scaling (BWS) experiment.
Methods: BWS tasks were developed according to a literature review and the focus group discussion. We used a balanced incomplete block design and blocking techniques to generate choice sets. The final BWS contains 11 attributes, with 6-choice scenarios in each block. The one-to-one, face-to-face BWS survey was conducted among type 2 diabetic patients in Jiangsu Province. Results were analyzed using count-based analysis and modelling approaches. We also conducted a subgroup analysis to observe preference heterogeneity.
Results: Data from 539 patients were available for analysis. The most desired information domain was the comparative effectiveness of new antidiabetic medications. It consists of the incidence of macrovascular complications, the length of extended life years, changes in health-related quality of life, the incidence of microvascular complications, and the control of glycated haemoglobin. Of all the attributes, the incidence of macrovascular complications was the primary concern. Patients' glycemic control and whether they had diabetes complications exerted a significant influence on their information needs.
Conclusions: Information on health benefits is of critical significance for diabetic patients. Patients have different information needs as their disease progresses. Personalized patient decision aids that integrate patient information needs and provide evidence of new antidiabetic medications are worthy of being established.
Patient Or Public Contribution: Before data collection, a pilot survey was carried out among diabetic patients to provide feedback on the acceptability and intelligibility of the attributes.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11061543 | PMC |
http://dx.doi.org/10.1111/hex.14059 | DOI Listing |
Diabetes Res Clin Pract
September 2025
Health Education Department, and Department of Endocrinology and Diabetes, Diabetes Treatment Center, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
Background: Despite advances, glycemic control in people with type 2 diabetes (PwT2D) treated with oral antidiabetic medications (ADMs) often remains suboptimal. Continuous glucose monitoring (CGM) has shown promise in diabetes management, offering real-time insights into glucose trends. This study evaluates the impact of transitioning from conventional self-monitoring of blood glucose (SMBG) to CGM on glycemic outcomes and self-management in PwT2D receiving oral ADMs.
View Article and Find Full Text PDFInt Immunopharmacol
September 2025
Department of Hepatobiliary and Hydatid Disease, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China; State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Urumqi, China. Electronic address:
Hepatic ischemia-reperfusion injury (HIRI) is a critical factor affecting the outcomes of liver surgeries, with inflammation and apoptosis playing pivotal roles in its pathogenesis. Empagliflozin, an anti-diabetic drug, has demonstrated hepatoprotective effects in various liver diseases, but its role in HIRI remains unclear. This study aimed to explore the protective mechanisms of empagliflozin against HIRI.
View Article and Find Full Text PDFDiabetes Metab Res Rev
September 2025
Interdisciplinary Department of Medicine, School of Medicine, University of Bari 'Aldo Moro', Bari, Italy.
Overweight and obesity represent common chronic metabolic disorders in the general population, and observed trends describe a substantial growth in the prevalence of weight excess also among individuals with type 1 diabetes (T1D), the so-called 'lean phenotype' of diabetes. The sharp rise of weight excess and obesity-related cardio-nephron-metabolic burdens observed in T2D is expected to produce similar consequences in T1D, leading to the urgent need to endorse therapeutic protocols as in most parts of the World no adjunctive treatments are approved for T1D, making weight excess management challenging in these individuals. The notable results shown by newer glucagon-like peptide 1 receptor agonists (GLP-1RAs) and emerging dual agonists, especially while managing cardio-metabolic burdens, in T2D have encouraged fervent anecdotal and non-anecdotal research also in T1D, indicating that non-insulin injective agents can be effective and safe.
View Article and Find Full Text PDFJ Prim Care Community Health
September 2025
Department of Family Medicine, College of Human Medicine, Michigan State University, Grand Rapids, MI, USA.
Aims: To identify risk factors for hyperglycemia in emergency department visits within 1 year following type 2 diabetes diagnosis.
Methods: In this retrospective cohort study, electronic medical record data from 3333 adult patients newly diagnosed with type 2 diabetes across 57 primary care clinics in West Michigan between April 2021 and January 2023 were analyzed. The primary outcome was hyperglycemia at ED encounters within 12 months of diagnosis.
Carbohydr Polym
November 2025
Department of Kidney Transplantation, Nephropathy Hospital, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China. Electronic address:
Islet transplantation offers a promising therapeutic strategy for type 1 diabetes patients with inadequate glycemic control or severe complications. Islet encapsulation using biocompatible materials presents a potential solution to reduce immune rejection. This study fabricated and characterized Schiff base hydrogels (CMOCs) composed of varying ratios of carboxymethyl chitosan (CMCS) and oxidized carboxymethyl starch (OCMS).
View Article and Find Full Text PDF